Skip to main navigation Skip to search Skip to main content

Evaluation of imidazo[2,1–b]thiazole-based anticancer agents in one decade (2011–2020): Current status and future prospects

  • University of Sharjah
  • Faculty of Pharmacy

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

Several reports have highlighted imidazo[2,1-b]thiazole derivatives as potential antiproliferative agents. They act through kinase inhibition, tubulin inhibition, and other molecular mechanisms of action. In the current article, we reviewed the imidazo[2,1-b]thiazole-based compounds that were reported as anticancer agents. Their biological characteristics as well as structure–activity relationship (SAR) have been reviewed and evaluated. Our main focus was on the reports published in the literature from 2011 to 2020.

Original languageEnglish
Article number115897
JournalBioorganic and Medicinal Chemistry
Volume29
DOIs
StatePublished - 1 Jan 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anticancer
  • Antiproliferative
  • Imidazo[2,1-b]thiazole
  • Imidazothiazole
  • Kinase inhibitor
  • Tubulin

Fingerprint

Dive into the research topics of 'Evaluation of imidazo[2,1–b]thiazole-based anticancer agents in one decade (2011–2020): Current status and future prospects'. Together they form a unique fingerprint.

Cite this